Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

| More on:
Health professional looking at a laptop.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares have underperformed the market over the last 12 months.

During this time, the biotechnology giant's shares have fallen 2%.

As a comparison, the ASX 200 index has risen approximately 12% over the same period.

Is this underperformance a buying opportunity or should you keep your powder dry for the time being? Let's see what analysts are saying about the company this month.

Are CSL shares a buy?

With earnings season now well and truly behind us, analysts have updated their financial models and recommendations accordingly.

The good news for shareholders (and potential investors) is that the general consensus is that CSL shares are meaningfully undervalued at current levels.

For example, no fewer than six major brokers have the equivalent of buy ratings on the company's shares with price targets that imply double-digit returns for investors buying at current prices.

One of those brokers is Jefferies, which currently has a buy rating and $338.50 price target on CSL's shares. This implies potential upside of 21% for investors from current levels.

Elsewhere, the team at UBS remains positive on CSL. It responded to the company's half year results lat month by retaining its buy rating with a $330.00 price target. This suggests that its shares could rise a very attractive 18% over the next 12 months.

Anyone else?

Over at Morgans, its analysts are fans of CSL. In fact, they are so positive they have named the company on their best ideas list once again this month. They explain:

While shares have struggled of late, we continue to view CSL as a key portfolio holding and sector pick, offering double-digit recovery in earnings growth as plasma collections increase, new products get approved and influenza vaccine uptake increases around ongoing concerns about respiratory viruses, with shares trading at 25x, a substantial discount (20%) to its long-term average.

Morgans currently has an add rating and $315.40 price target, which offers potential upside of approximately 13%.

Even Citi, which downgraded CSL's shares to a neutral rating last month, has a price target of $305.00, which offers decent 9% upside for investors.

Overall, the broker community appears to see the risk/reward on offer with CSL shares as quite compelling based on where they trade today.

But as always, time will tell if these analysts are on the money with their recommendations with this one.

Citigroup is an advertising partner of The Ascent, a Motley Fool company. Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »